Literature DB >> 29147616

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Constance Le Goux1, Sophie Vacher1, Géraldine Pignot2, Mathilde Sibony3, Nicolas Barry Delongchamps4, Benoit Terris3, Eliane Piaggio5, Marc Zerbib4, Diane Damotte3,6, Ivan Bieche1,7.   

Abstract

Immunotherapy for bladder cancer has given promising results. Here we aimed to evaluate the possible involvement and prognostic value of 33 genes involved in the immune response during bladder carcinogenesis. Expression levels were assessed by quantitative real-time RT-PCR in normal and tumor human bladder samples. Immunohistochemistry was performed to evaluate the protein expression of 2 genes and relation of the mRNA and protein levels was analyzed. Tumors were obtained from 154 patients (83 with muscle-invasive bladder cancer [MIBC] and 71 non-MIBC [NMIBC]) who underwent transurethral bladder resection or radical cystectomy between 2002 and 2006. All patients signed an informed consent. Results of molecular analyses were coupled with survival analyses. Overall, 25 genes (75.8%) were significantly overexpressed in MIBC and 15 (45.5%) were deregulated in NMIBC as compared with normal tissue. On multivariate analysis, risk of NMIBC recurrence was increased with high FOXP3/CD8 ratio and overexpression of OX40L (p = 0.016 and p = 0.0039, respectively). In MIBC, a molecular signature of 3 genes (OX40L, CD8 and TIGIT) was significantly associated with prognosis in terms of recurrence-free and overall survival (p = 0.0007 and p = 0.007). RT-PCR findings were confirmed by immunohistochemistry for CD8 and FOXP3, with high association between mRNA and protein levels. Finally, risk of recurrence of non-muscle-invasive bladder cancer was increased with high FOXP3/CD8 ratio and OX40L overexpression. We identified a 3 gene molecular signature associated with prognosis of muscle-invasive bladder cancer. These results confirm the useful role of immune checkpoints in bladder carcinogenesis and suggest targets for therapy.

Entities:  

Keywords:  Bladder cancer; RT-PCR; immune checkpoints; immunohistochemistry; prognostic factor

Year:  2017        PMID: 29147616      PMCID: PMC5674963          DOI: 10.1080/2162402X.2017.1358330

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  18 in total

1.  The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses.

Authors:  Robert J Johnston; Xin Yu; Jane L Grogan
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

2.  CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.

Authors:  Eiji Shinto; Kazuo Hase; Yojiro Hashiguchi; Akinori Sekizawa; Hideki Ueno; Atsushi Shikina; Yoshiki Kajiwara; Hirotoshi Kobayashi; Megumi Ishiguro; Junji Yamamoto
Journal:  Ann Surg Oncol       Date:  2014-02-25       Impact factor: 5.344

3.  Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?

Authors:  Tom Powles
Journal:  Eur Urol       Date:  2015-03-21       Impact factor: 20.096

Review 4.  Shaping of an effective immune microenvironment to and by cancer cells.

Authors:  Etienne Becht; Jeremy Goc; Claire Germain; Nicolas A Giraldo; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman
Journal:  Cancer Immunol Immunother       Date:  2014-08-12       Impact factor: 6.968

5.  A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.

Authors:  Milena P Mak; Pan Tong; Lixia Diao; Robert J Cardnell; Don L Gibbons; William N William; Ferdinandos Skoulidis; Edwin R Parra; Jaime Rodriguez-Canales; Ignacio I Wistuba; John V Heymach; John N Weinstein; Kevin R Coombes; Jing Wang; Lauren Averett Byers
Journal:  Clin Cancer Res       Date:  2015-09-29       Impact factor: 12.531

6.  The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.

Authors:  T Horn; J Laus; A K Seitz; T Maurer; S C Schmid; P Wolf; B Haller; M Winkler; M Retz; R Nawroth; J E Gschwend; H R Kübler; J Slotta-Huspenina
Journal:  World J Urol       Date:  2015-06-09       Impact factor: 4.226

7.  Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer.

Authors:  Zhengbin Shen; Shuang Zhou; Yanna Wang; Ri-lun Li; Cuiping Zhong; Chunmin Liang; Yihong Sun
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-11       Impact factor: 4.553

8.  Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction.

Authors:  Junzhou Niu; Changli Jiang; Chunying Li; Ling Liu; Kai Li; Zhe Jian; Tianwen Gao
Journal:  Cancer Immunol Immunother       Date:  2011-05-06       Impact factor: 6.968

9.  Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.

Authors:  Hiroyuki Suzuki; Nobuhito Chikazawa; Takehiko Tasaka; Junji Wada; Akio Yamasaki; Yoshiki Kitaura; Masae Sozaki; Masao Tanaka; Hideya Onishi; Takashi Morisaki; Mitsuo Katano
Journal:  Cancer Immunol Immunother       Date:  2009-11-12       Impact factor: 6.968

10.  Adult-onset immunodeficiency in Thailand and Taiwan.

Authors:  Sarah K Browne; Peter D Burbelo; Ploenchan Chetchotisakd; Yupin Suputtamongkol; Sasisopin Kiertiburanakul; Pamela A Shaw; Jennifer L Kirk; Kamonwan Jutivorakool; Rifat Zaman; Li Ding; Amy P Hsu; Smita Y Patel; Kenneth N Olivier; Viraphong Lulitanond; Piroon Mootsikapun; Siriluck Anunnatsiri; Nasikarn Angkasekwinai; Boonmee Sathapatayavongs; Po-Ren Hsueh; Chi-Chang Shieh; Margaret R Brown; Wanna Thongnoppakhun; Reginald Claypool; Elizabeth P Sampaio; Charin Thepthai; Duangdao Waywa; Camilla Dacombe; Yona Reizes; Adrian M Zelazny; Paul Saleeb; Lindsey B Rosen; Allen Mo; Michael Iadarola; Steven M Holland
Journal:  N Engl J Med       Date:  2012-08-23       Impact factor: 91.245

View more
  7 in total

Review 1.  Modelling the tumor immune microenvironment for precision immunotherapy.

Authors:  Nathan J Mackenzie; Clarissa Nicholls; Abby R Templeton; Mahasha Pj Perera; Penny L Jeffery; Kate Zimmermann; Arutha Kulasinghe; Tony J Kenna; Ian Vela; Elizabeth D Williams; Patrick B Thomas
Journal:  Clin Transl Immunology       Date:  2022-06-26

2.  Immunoregulated insulitis and slow-progressing type 1 diabetes after duodenopancreatectomy.

Authors:  Pauline Faucher; Frédéric Beuvon; Daniela Fignani; Guido Sebastiani; Georgia Afonso; Zhicheng Zhou; Bertrand Dousset; Christian Boitard; Francesco Dotta; Roberto Mallone; Etienne Larger
Journal:  Diabetologia       Date:  2021-09-14       Impact factor: 10.122

3.  Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Authors:  Edith Borcoman; Philippe De La Rochere; Wilfrid Richer; Sophie Vacher; Walid Chemlali; Clémentine Krucker; Nanour Sirab; Francois Radvanyi; Yves Allory; Géraldine Pignot; Nicolas Barry de Longchamps; Diane Damotte; Didier Meseure; Christine Sedlik; Ivan Bieche; Eliane Piaggio
Journal:  Oncoimmunology       Date:  2019-03-16       Impact factor: 8.110

4.  A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer.

Authors:  Xiaonan Zheng; Xianghong Zhou; Hang Xu; Di Jin; Lu Yang; Bairong Shen; Shi Qiu; Jianzhong Ai; Qiang Wei
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

5.  Identification of 9-Core Immune-Related Genes in Bladder Urothelial Carcinoma Prognosis.

Authors:  Lei Na; Yu Bai; Yu Sun; Zhuo Wang; Wei Wang; Lin Yuan; Chenghai Zhao
Journal:  Front Oncol       Date:  2020-07-08       Impact factor: 6.244

6.  Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer.

Authors:  Run Shi; Xuanwen Bao; Paul Rogowski; Christian Schäfer; Nina-Sophie Schmidt-Hegemann; Kristian Unger; Shun Lu; Jing Sun; Alexander Buchner; Christian Stief; Claus Belka; Minglun Li
Journal:  Cancers (Basel)       Date:  2020-05-02       Impact factor: 6.639

7.  Identification of a 13‑mRNA signature for predicting disease progression and prognosis in patients with bladder cancer.

Authors:  Hubin Yin; Chen Zhang; Xin Gou; Weiyang He; Daoju Gan
Journal:  Oncol Rep       Date:  2019-12-12       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.